Now, considering that the label specifies HER2 TKD-activating mutations tested from tumor tissue or plasma, how should community oncologists think about biomarker testing for the subgroup, given that HER2 alterations in lung cancer can also encompass perhaps amplification, which may not be captured the same way?

Yeah.

So precision oncology start with, uh, testing and then detection and the interpretation of the reports.

So HER2 is also called ERBB2.

There are different type of genetic alterations can happen, uh, actually in different type of solid tumors.

In lung cancer, the mutation in the kinase domain, either as a mutation or as a short genomic insertion, is oncogenic, can leads to lung cancer development.

And then accordingly, precision oncology approach, for example, a HER2-targeting TKI, like cevoburtinib, can reverse the oncogenesis, so patient derive benefit.

And, you know, since this re-remains an accelerated approval based on response rates and duration of response, what confirmatory data will be needed to convert this into a full approval, and how confident are you that it will get to that status?

So let's start with where you grew up in China, how you got interested in medicine, what were your role models, and then how you made your way to the United States and subsequently to MD Anderson.

I was born and raised in Beijing, China.

My parents are scholars.

Basically, they're both scientific editors.

So I grew up in the household, have a lot of focus on academic achievement.

So in China, the system is at the end of high school, everyone take a college entrance exam.

and then that placed the high school kids into different colleges.

And then what is the thought process for each stage at this point in lung cancer? We'll start with non-small cell lung cancer.